Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Observe this TAVI case featuring pulseless electrical activity due to an unforeseen acute occlusion of the right coronary artery, and discover the strategies employed to address and resolve this critical complication.

Luigi Biasco reports the best of Dj Lakkireddy (Overland Park, USA)'s presentation of the AMULET IDE trial at the Monday, August 30 Hot Line session of the ESC Congress 2021.

Paris, France, 20-23 May 2025. The EuroPCR Course Directors have selected 3 major late-breaking trials that will be presented for the first time during the 2025 edition of EuroPCR. These trials were selected because of their design, results, and potential to impact practice, among them is the...

Jonathan Curio provides his take on the MitrAI score study which was presented by Luigi Biasco at ESC Congress 2024 in London.

What’s the safest approach when surgical options are off the table? This real-life case shows how complex coronary revascularsation and TAVI were performed in a single session, supported by Impella.

Explore the rationale behind the sequence, the device choices, and the outcome in a high-risk patient with...

Alex Sticchi provides his take on the results of the OPINION trial presented by Yang Wang at the ESC Congress 2025 in Madrid.

Daniele Giacoppo reports the main results of the RENOVATE-COMPLEX-PCI trial presented by Joo-Yong Hahn, from the Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, in a Late-Breaking Trial session at the American College of Cardiology (ACC) 2023 / World...

Ali Nazmi Calik provides his take on OPTION, which was presented during AHA 2022 in Chicago.

A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak has been declared a Public Health Emergency of International Concern by the WHO since January 2020. The rapid, exponential, increase in confirmed cases makes prevention and control of coronavirus disease (COVID-19) extremely critical. Although clinical manifestations of...

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.

Claudio Laudani and Daniele Giacoppo report the main results of the ILUMIEN IV trial presented by Ziad Ali, from the St. Francis Hospital, Roslyn, and Clinical Trials Center, Cardiovascular Research Foundation, New York, in a Hot Line session at the European Society of Cardiology congress 2023...